Asia
GenFleet Therapeutics Says RAS Inhibitor Program Unrelated to RevMed IP Dispute; Shares Down 7%
GenFleet Therapeutics (Shanghai) (HKG:2595) said correspondence issued by Revolution Medicines on patent and trade secret disputes over RAS inhibitors is unrelated to the company, according to a Tuesday Hong Kong bourse filing.GenFleet said all entities, products, and disputed matters referenced are "entirely unrelated" to it.The company added GFH276, which is developed on fully independent, original, and proprietary intellectual property, with no exposure to such risks.The company said it has built a global patent portfolio for its Pan RAS inhibitor program, with the core patent for GFH276's compound structure published on March 6, 2025, and protection expected to extend to 2044.GenFleet's shares fell nearly 7% in recent trade.
HKG:2595
